Merck & Co. Company Profile (NYSE:MRK)

Analyst Ratings

Consensus Ratings for Merck & Co. (NYSE:MRK) (?)
Ratings Breakdown: 13 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.24)
Consensus Price Target: €60.07 (2.13% upside)

Analysts' Ratings History for Merck & Co. (NYSE:MRK)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Jefferies GroupBoost Price TargetHold$50.00 -> $53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Leerink SwannReiterated RatingHold$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Credit Suisse Group AGReiterated RatingHold$59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016ArgusReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016Morgan StanleyReiterated RatingHold$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Berenberg BankInitiated CoverageHold$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015Sanford C. BernsteinLower Price Target$69.00 -> $64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2015Deutsche Bank AGReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Piper Jaffray Cos.Reiterated RatingHold$62.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2014GuggenheimInitiated CoverageNeutral$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2014Main First Bank AGUpgradeUnderperform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Merck & Co. (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/29/2016        
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2012$1.02$1.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2012$0.98$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$0.95$0.97ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2011$0.91$0.94ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2011$0.94$0.95ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2011$0.84$0.92ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2011$0.83$0.88ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merck & Co. (NYSE:MRK)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20162$0.95$0.98$0.97
Q4 20162$0.89$1.01$0.95
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Merck & Co. (NYSE:MRK)
Annual Dividend:$1.84
Dividend Yield:3.13%
Payout Ratio:112.88% (Based on Trailing 12 Months of Earnings)
49.46% (Based on Current Year Consensus EPS Estimate)
49.60% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.30% (3 Year Average)

Dividend History for Merck & Co. (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
5/24/2016quarterly€0.463.25%6/13/20166/15/20167/8/2016Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016quarterly€0.463.64%3/11/20163/15/20164/7/2016Tweet This Announcement  Share This Announcement on StockTwits
11/24/2015quarterly€0.463.43%12/11/201512/15/20151/8/2016Tweet This Announcement  Share This Announcement on StockTwits
7/22/2015quarterly€0.453.1%9/11/20159/15/201510/7/2015Tweet This Announcement  Share This Announcement on StockTwits
5/26/2015quarterly€0.453.03%6/11/20156/15/20157/8/2015Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015quarterly€0.453.05%3/12/20153/16/20154/8/2015Tweet This Announcement  Share This Announcement on StockTwits
11/25/2014quarterly€0.453.01%12/11/201412/15/20141/8/2015Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014quarterly€0.443.02%9/11/20149/15/201410/7/2014Tweet This Announcement  Share This Announcement on StockTwits
5/27/2014quarterly€0.443.12%6/12/20146/16/20147/8/2014Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014quarterly€0.443.13%3/13/20143/17/20144/7/2014Tweet This Announcement  Share This Announcement on StockTwits
11/26/2013quarterly€0.443.53%12/12/201312/16/20131/8/2014Tweet This Announcement  Share This Announcement on StockTwits
7/24/2013quarterly€0.433.57%9/12/20139/16/201310/7/2013Tweet This Announcement  Share This Announcement on StockTwits
5/28/2013quarterly€0.433.67%6/13/20136/17/20137/8/2013Tweet This Announcement  Share This Announcement on StockTwits
2/26/2013quarterly€0.434%3/13/20133/15/20134/5/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Co. (NYSE:MRK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/5/2016Kenneth C FrazierCEOSell60,000€58.00€3,480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Weir Mirian M GraddickInsiderSell45,000€57.99€2,609,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Adam H SchechterEVPSell50,000€57.69€2,884,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Weir Mirian M GraddickInsiderSell30,000€57.49€1,724,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Clark GolestaniEVPSell39,877€54.79€2,184,860.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2016Kenneth C FrazierCEOSell131,040€56.11€7,352,654.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Wendell P. WeeksDirectorSell5,000€55.53€277,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Adele D. AmbroseinsiderSell37,313€55.08€2,055,200.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Kenneth C. FrazierCEOSell18,666€54.69€1,020,843.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Peter C. WendellDirectorSell5,000€54.85€274,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Adam H SchechterEVPSell10,634€60.44€642,718.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Julie L GerberdingEVPSell38,368€60.99€2,340,064.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Bruce N KuhlikInsiderSell56,064€60.20€3,375,052.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2015Bruce N KuhlikInsiderSell156,902€59.82€9,385,877.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2015Michael J HolstonEVPSell95,624€59.84€5,722,140.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Kenneth C FrazierCEOSell5,164€58.67€302,971.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Willie A DeeseInsiderSell135,864€58.56€7,956,195.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Peter C WendellDirectorSell5,000€58.76€293,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Adam H SchechterEVPSell74,200€62.48€4,636,016.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2015Kenneth C FrazierCEOSell8,840€62.47€552,234.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Kenneth C FrazierCEOSell9,846€60.00€590,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Bruce N KuhlikInsiderSell50,000€62.00€3,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014Rochelle B LazarusDirectorSell10,000€59.63€596,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Wendell P WeeksDirectorSell5,000€59.13€295,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Kenneth C FrazierCEOSell10,000€57.98€579,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Kenneth C FrazierCEOSell9,895€59.73€591,028.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Kenneth C FrazierCEOSell9,814€60.48€593,550.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Adam H SchechterEVPSell22,000€59.70€1,313,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Kenneth C FrazierCEOSell10,058€57.00€573,306.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Adele D AmbroseInsiderSell28,669€56.64€1,623,812.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Kenneth C FrazierCEOSell9,987€58.03€579,545.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Weir Mirian M GraddickInsiderSell180,047€59.16€10,651,580.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014Willie A DeeseInsiderSell72,290€58.26€4,211,615.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Kenneth C FrazierCEOSell9,985€58.06€579,729.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Adam SchechterEVPSell10,527€55.91€588,564.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2014Kenneth FrazierCEOSell10,047€57.24€575,090.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2014Bruce KuhlikInsiderSell145,225€56.43€8,195,046.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Clark GolestaniEVPSell5,990€55.47€332,265.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2014Bridgette HellerVPSell43,870€55.04€2,414,604.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Adam SchechterEVPSell18,000€55.61€1,000,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014John CananInsiderSell10,000€55.70€557,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Kenneth FrazierCEOSell41,520€54.52€2,263,670.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Peter WendellDirectorSell5,000€54.44€272,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Willie DeeseInsiderSell50,000€54.68€2,734,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2013Willie DeeseInsiderSell50,638€48.55€2,458,474.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Adele D AmbroseInsiderSell34,208€46.66€1,596,145.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Bridgette P HellerVPSell5,404€46.15€249,394.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2012Willie A DeeseInsiderSell62,324€44.26€2,758,460.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merck & Co. (NYSE:MRK)
DateHeadline
07/23/16 04:52 PMMerck & Co. Inc. (NYSE:MRK) Attains FDA Authorization For Bravecto- Transocean (NYSE:RIG), Nucor Corporation ... - Seneca Globe
07/23/16 04:52 PMMerck & Co. (NYSE:MRK) Requested By FDA For submission of new data For MODIFY I- II Clinical Trials- Aetna (AET ... - Seneca Globe
07/23/16 04:52 PMHuntington Bancshares (NASDAQ:HBAN) & Merck & Co., Inc. (NYSE:MRK) Stock's Buzzers - Money News (press release)
07/23/16 04:52 PMMarket Exclusive's Inside the FDA: This Week Bezlotoxumab from Merck & Co., Inc. (MRK) - Insider Monkey (blog)
07/23/16 04:52 PMStock to Track: Merck & Co. Inc. (NYSE:MRK) - News Oracle
07/23/16 04:52 PMMerck & Co., Inc. (NYSE:MRK) Embattled By Over 400 Pay Discrimination Claims - Market Exclusive
07/23/16 10:41 AMIn Case You Missed It, 5 New Lung Cancer Drugs Have Been Approved Since October -
07/23/16 09:10 AMMerck & Company Inc. (new) (MRK) Closes 0.05% Up on the Day for July 22
07/23/16 09:10 AMMerck (ETR:MRK) stock price target upped to 99EUR as recorded today by Independent Research GmbH
07/23/16 09:10 AMMerck & Co., Inc. (NYSE:MRK), Morgan Stanley(NYSE:MS)
07/22/16 05:09 PMCompany Update (NYSE:MRK): Data
07/22/16 12:25 PMMarket Exclusive’s Inside the FDA: This Week Bezlotoxumab from Merck & Co., Inc. (MRK) -
07/22/16 11:43 AMMerck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS - Merck & Co., Inc. (NYSE: MRK) revealed efficacy, as well as, safety data in previously untreated adults with HIV-1 infection for its investigational once-daily formulation of ISENTRESS from the ongoing final stage pivotal study known as ONCEMRK. It is also called as raltegravir 600 mg (to be given as 2 x 600 mg). Merck said the data assessing efficacy and safety at the end of 48 weeks of therapy were presented as a late-breaking abstract at the 21st International AIDS Conference (AIDS 2016) being held in South Africa between July 18 and 22. The drug maker said that at the end ...Full story available on Benzinga.com
07/22/16 08:15 AMMerck Reports Data From Phase 3 ISENTRESS Trial; EMA Accepts File Application
07/22/16 07:18 AMData for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... - [at noodls] - KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for ...
07/21/16 05:36 PMWoodley Farra Manion Portfolio Management Inc buys $21976525 stake in Merck & Co. (MRK) - Trade Calls
07/21/16 05:36 PMTrading Notes: Reviewing Stock Performance for Merck & Co. Inc. (NYSE:MRK) - Press Telegraph
07/21/16 05:36 PMNotable Analyst Coverage: ConocoPhillips (NYSE:COP), Merck & Co., Inc. (NYSE:MRK) - Review Fortune
07/21/16 05:36 PMHow Merck & Co., Inc. Ranks As a Top Analyst Pick (MRK) - Investorplace.com
07/21/16 05:36 PMNorth American Management Corp Lowers stake in Merck & Co. (MRK) - TheFounders Daily
07/21/16 04:24 PMMore Than 400 Women Are Now Suing Merck for Unequal Pay -
07/21/16 04:00 PMMerck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs - [Business Wire] - Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administration’s approval of BRAVECTO® for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose.
07/21/16 03:30 PM4:30 pm Merck announces the FDA has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab -
07/21/16 03:30 PMMerck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab - [Business Wire] - Merck , known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C.
07/21/16 03:20 PMSorry, You Can't Buy This Hot Biotech -- At Least Not Directly -
07/21/16 08:06 AMBankhaus Lampe KG reported on (ETR:MRK) Merck, raising its target price to 102EUR earlier today
07/21/16 08:06 AMMerck & Company Inc. (new) (MRK) Closes 0.22% Up on the Day for July 20
07/21/16 08:06 AMBarry Investment Advisors Lowers stake in Merck & Co. (MRK)
07/21/16 08:05 AMMerck & Co., Inc. (NYSE:MRK) KGaA To Build A New Life Science Hub Worthy $115 Million In Massachusetts
07/21/16 08:05 AMEastern Bank Lowers stake in Merck & Co. (MRK)
07/21/16 06:25 AMHow Merck & Co., Inc. Ranks As a Top Analyst Pick (MRK) - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips A study of analyst recommendations at the major brokerages shows that Merck is the #15 broker pick out of the 30 Dow stocks The post How Merck & Co., Inc. Ranks As a Top Analyst Pick (MRK) appeared first on InvestorPlace.
07/20/16 05:57 PMStock Analysis review: Merck & Co. Inc. (MRK) - News Oracle
07/20/16 05:57 PMMerck & Co., Inc. (NYSE:MRK) KGaA To Build A New Life Science Hub Worthy $115 Million In Massachusetts - Market Exclusive
07/20/16 08:13 AMMerck & Co. Inc. (NYSE:MRK) from Drug Manufacturers – Major – Todays Top Gains - Twin County News
07/20/16 08:13 AMAnalyst No Longer Bullish Towards Merck & Co., Inc. (MRK) - Smarter Analyst
07/20/16 08:12 AMMerck & Co., Inc. (MRK) and OpGen Inc (OPGN) Are Quietly Changing The Infectious Disease Landscape - Insider Monkey (blog)
07/20/16 06:47 AMWhat's behind heavy put volume in Merck -
07/19/16 05:24 PMA report released today by equinet AG about Merck(ETR:MRK) raises the target price to 85EUR
07/19/16 05:24 PMGeode Capital Management LLC Purchases 353474 Shares of Merck & Co. (MRK)
07/19/16 05:24 PM(MRK) Shares Bought by Loomis Sayles & Co
07/19/16 05:24 PMAbner Herrman Brock buys $16164967 stake in Merck & Co. (MRK)
07/19/16 09:51 AMHealthcare Stocks in Limelight: AbbVie Inc (NYSE:ABBV), Merck & Co., Inc. (NYSE:MRK) - Post Registrar
07/19/16 09:51 AMLong Term Value Play: Merck & Co. Inc. (NYSE:MRK) - TGP
07/19/16 09:51 AMAttentive Stocks in Active Notes- Merck & Co. Inc. (NYSE:MRK), AstraZeneca PLC (NYSE:AZN) - Seneca Globe
07/19/16 09:51 AMHot Stock under Consideration: Merck & Co. Inc. (NYSE:MRK) - News Oracle
07/19/16 09:51 AMMerck & Co., Inc. (NYSE:MRK) and OpGen Inc (NASDAQ:OPGN) Are Quietly Changing The Infectious Disease ... - Market Exclusive
07/19/16 09:51 AMAbner Herrman Brock buys $16164967 stake in Merck & Co. (MRK) - Trade Calls
07/18/16 05:26 PMAnalyst Downgrades: 3D Systems Corporation, Cypress Semiconductor Corporation, and Merck & Co., Inc. - Schaeffers Research (blog)
07/18/16 05:26 PMTrading Recap: Active Stock Focus on Merck & Co. Inc. (NYSE:MRK) - TGP
07/18/16 05:26 PMStock Positive on the Year: Merck & Co. Inc. (NYSE:MRK) - TGP

Social

About Merck & Co.

Merck & Co. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $58.82
  • 50 Day Moving Average: $57.65
  • 200 Day Moving Average: $54.20
  • P/E Ratio: 36.06
  • P/E Growth: 3.10
  • Market Cap: $162.82B
  • Beta: 0.66
  • Current Year EPS Consensus Estimate: $3.72 EPS
  • Next Year EPS Consensus Estimate: $3.71 EPS
Additional Links:
Merck & Co. (NYSE:MRK) Chart for Sunday, July, 24, 2016